← brief for 2026-08-13 · People & money

Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney disease: SOST and DDK1 inhibition in renal osteodystrophy

Paper D Peer reviewed Preclinical

Key takeaways

This study used bispecific antibodies to target two proteins linked to bone loss in kidney disease. It was done in mice and showed promise for treating renal osteodystrophy (bone-mineral disease). Results are not yet confirmed in humans.

Who did this work

Worachet Promruk · Soher; id_orcid 0000-0001-5263-8557 Jayash · Chartinun Chutoe (Cancer Genetics (United States)) · Hua Zhu Ke (Anglia Ruskin University) · Xi Liu · Rachel Wade · Alexander von Kriegsheim (Edinburgh Cancer Research) · William P. Cawthorn (8354286) (Neurological Surgery) · Katherine A Staines (University of Brighton) · Larry Stephen · Colin Farquharson

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-13
https://doi.org/10.1038/s41413-026-00556-y